[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336637-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336637-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","risk-of-second-malignancies-and-t-cell-lymphoma-after-car-t-cell-therapy-manuscript","Risk of Second Malignancies and T-Cell Lymphoma after CAR T-Cell Therapy - Manuscript","","Secondary cancer risk after CAR T-cell therapy is an emerging concern, particularly T-cell neoplasms potentially related to viral vector integration. The study reviews Stanford experience with adoptive cellular CAR therapy since 2016 and analyzes the occurrence of second malignancies. In a case of secondary T-cell lymphoma, extensive molecular, genetic, and cellular methods characterize the tumors, CAR-T cells, and normal hematopoietic cells. Across 724 patients, a rare lethal T-cell lymphoma is identified.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/risk-of-second-malignancies-and-t-cell-lymphoma-after-car-t-cell-therapy-manuscript/336637/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/risk-of-second-malignancies-and-t-cell-lymphoma-after-car-t-cell-therapy-manuscript/336637.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is secondary cancer risk after CAR T-cell therapy a concern?","Question",{"text":63,"@type":64},"Secondary cancer risk is an emerging issue, especially T-cell neoplasms that may relate to viral vector integration after CAR T-cell therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the occurrence of second malignancies assessed in this study?",{"text":68,"@type":64},"Clinical experience with adoptive cellular CAR therapy at Stanford since 2016 was reviewed, and second malignancies were ascertained.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find regarding viral vector integration in the reported lymphoma case?",{"text":72,"@type":64},"Multiple techniques found no evidence of oncogenic retroviral integration, even though both lymphoma cases were EBV+ and linked to DNMT3A and TET2 mutant clonal hematopoiesis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336637,1790193854,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>N Engl J Med. Author manuscript; available in PMC 2024 August 21. |\n| --- | --- |\n\nPublished in final edited form as:  \nN Engl J Med. 2024 June 13; 390(22): 2047–2060. doi:10.1056/NEJMoa2401361 .  \nRisk of second malignancies and T-cell lymphoma after chimeric antigen receptor T-cell therapy  \nMark P. Hamilton, M. D., Ph. D. 1,2,3 , Takeshi Sugio, M. D., Ph. D. 1,4 , Troy Noordenbos, M. D., Ph. D. 1,4 , Shuyu Shi, B. Med.5 , Philip L. Bulterys, M. D., Ph. D.6 , Chih Long Liu, Ph. D. 1,4 , Xiaoman Kang, B.S. 1,4 , Mari N. Olsen, B.S. 1,4 , Zinaida Good, Ph. D.2,7 , Saurabh Dahiya, M. D., F.A.C. P.2,3 , Matthew J. Frank, M. D., Ph. D.2,3 , Bita Sahaf, Ph. D.2 , Crystal L. Mackall, M. D.2,4,8 , Dita Gratzinger, M. D., Ph. D.6 , Maximilian Diehn, M. D., Ph. D.4,9,10 , Ash A. Alizadeh, M. D., Ph. D. 1,4,10 , David B. Miklos, M. D., Ph. D.2,3,4  \n1 Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.  \n2Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.  \n3 Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.  \n4Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA  \n5 Department of Bioengineering, Stanford University Schools of Medicine and Engineering, Stanford, CA94305, USA.  \n6 Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.  \n7 Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, 94305, USA  \n8 Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA  \n9 Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.  \n10 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, 94305, USA  \nAbstract  \nBackground—Secondary cancer risk after CAR T-cell therapy is an emerging concern,  \nespecially T-cell neoplasms related to viral vector integration.  \nThis Author Accepted Manuscript is licensed for use under the CC-BY-NC-ND license.  \nCorresponding Author: Dr. Ash A. Alizadeh, [arasha@stanford.edu](arasha@stanford.edu).  \nDr. Hamilton, Dr. Sugio, and Dr. Noordenbos contributed equally to this article.  \nDr. Alizadeh and Dr. Miklos contributed equally to this article.  \nDisclosure forms provided by the authors are available with the full text of this article [at](at NEJM.org)[ NEJM.org](at NEJM.org).  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nHamilton et al. Page 2  \nMethods—The clinical experience with adoptive cellular CAR therapy at Stanford since 2016 was reviewed and the occurrence of second malignancies ascertained. In one case of secondary T-cell lymphoma, a broad array of molecular, genetic, and cellular techniques were used to  \ninterrogate the tumor, the CAR-T cells, and the normal hematopoietic cells in the patient.  \nResults—We describe the second cancer risk in 724 patients receiving T-cell therapies at our center. We identified a lethal T-cell lymphoma after axicabtagene ciloleucel therapy for DLBCL, and deeply profiled both tumors. Each lymphoma had molecularly distinct immunophenotypesand genomic profiles, but both were EBV+ and associated with DNMT3A and TET2 mutant clonal hematopoiesis. We found no evidence of oncogenic retroviral integration using multiple techniques.  \nConclusion—These results highlight the rarity of secondary neoplasms, while providing a framework for defining clonal relationships and viral vector monitoring.  \n(Funded by NCI and others.)  \nIntroduction:  \nDespite the remarkable therapeutic efficacy of commercial chimeric antigen receptor (CAR) T-cell therapies, 1-9 concerns ov","cbCaifMot1BBCNSP","https://ap.wps.com/l/cbCaifMot1BBCNSP","pdf",1325102,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Concerns about toxicities and reported cases\n## FDA alert and evidence of additional cases\n## Current study approach and objectives\n# Case report and study design\n## EBV-positive TCL and timing after CAR therapy\n## Molecular profiling and longitudinal monitoring","[{\"question\":\"Why is secondary cancer risk after CAR T-cell therapy a concern?\",\"answer\":\"Secondary cancer risk is an emerging issue, especially T-cell neoplasms that may relate to viral vector integration after CAR T-cell therapy.\"},{\"question\":\"How was the occurrence of second malignancies assessed in this study?\",\"answer\":\"Clinical experience with adoptive cellular CAR therapy at Stanford since 2016 was reviewed, and second malignancies were ascertained.\"},{\"question\":\"What did the study find regarding viral vector integration in the reported lymphoma case?\",\"answer\":\"Multiple techniques found no evidence of oncogenic retroviral integration, even though both lymphoma cases were EBV+ and linked to DNMT3A and TET2 mutant clonal hematopoiesis.\"}]","Risk of Second Malignancies and T-Cell Lymphoma after CAR T-Cell Therapy - Manuscript | PDF",1790015975,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4512103108eab5289c2a4bcf73689a3a.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/690e9e73db6f0b54a0411eeb1f7b01af.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/150cef4acddd322d7da3c2da6ed0012f.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cc7d355c428339437c8990f838f97ea.webp",980,1268]